CAMBRIDGE, Mass. – August 15, 2011 – Selventa™, a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, today announced that the Company’s Chief Executive Officer, David de Graaf, has recently been appointed as a Scientific Advisory Board member for the SIB Swiss Institute of Bioinformatics.
“We are very happy to have David as a member of the SIB Scientific Advisory Board,” said Ron Appel, Ph.D., Executive Director at SIB and Professor of Bioinformatics at the University of Geneva. “David’s thoughtful insights, drawn from his extensive experience in systems biology, will be instrumental in helping to drive the development of SIB’s many bioinformatics resources. He is one of the pioneering minds of systems biology and we are looking forward to a fruitful and brilliant cooperation.”
The SIB is an academic, non-profit foundation established in 1998 to coordinate research and education in bioinformatics throughout Switzerland. The SIB’s mission is to provide world-class core bioinformatics resources to the global research community in key fields such as genomics, proteomics and systems biology, such as UniProtKB/Swiss-Prot, SWISS-MODEL or STRING. Dr. de Graaf was appointed on July 1 by the SIB Foundation Council at its annual meeting, together with Professor Alexey I. Nesvizhskii from the University of Michigan in Ann Arbor. They join Professors Manolo Gouy (Chairman), Christine Orengo, Ron Shamir, Anna Tramontano and Alfonso Valencia, five distinguished experts who have been serving on the Scientific Advisory Board for several years.
“I feel privileged to be elected as a Scientific Advisory Board member at SIB,” said David de Graaf, Ph.D., President and CEO of Selventa. “Effective interpretation of siloed large-scale data is a key initial step in translating critical biological information into clinical applications. I am excited to engage SIB’s distinguished advisors and participate in recommending future initiatives that impact life sciences institutions globally.”
Founded in 2002 and privately-held, Selventa helps clients find optimal treatments for the right patients by offering scientific consulting services, software and strategic partnerships. The company analyzes molecular patient data, accelerates the development process and clarifies therapeutics and diagnostics decisions. Selventa engages in short-, mid- and long-term relationships with top-tier pharmaceutical and life science companies to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases, inflammation and drug safety. For more information, visit www.selventa.com.
About SIB Swiss Institute of Bioinformatics
SIB Swiss Institute of Bioinformatics is an academic not-for-profit foundation recognised of public utility. It federates bioinformatics activities throughout Switzerland. Its two-fold mission is to provide world-class core bioinformatics resources to the national and international life science research community in key fields such as genomics, proteomics and systems biology; as well as to lead and coordinate the field of bioinformatics in Switzerland. It has a long-standing tradition of producing state-of-the-art software for the life science research community, as well as carefully annotated databases. SIB includes 31 world-class research and service groups, which gather more than 450 researchers, in the fields of proteomics, transcriptomics, genomics, systems biology, structural bioinformatics, evolutionary bioinformatics, modeling, imaging, biophysics, and population genetics in Basel, Bern, Fribourg, Geneva, Lausanne, and Zurich. SIB expertise is widely appreciated and its services are used by Life Science researchers worldwide. For more information, visit www.isb-sib.ch.
For more information, please contact:
Diane H. Song, Ph.D., 617-547-5421 x235
Paul Kidwell, 617-296-3854
Irène Perovsek, +41 21 692 40 54